Previous close | 50.58 |
Open | 50.82 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 50.26 - 50.82 |
52-week range | 50.26 - 50.82 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 31 Oct 2022 - 04 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 38.30 |
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.